Literature DB >> 32130705

Exploiting Cancer Cells Metabolic Adaptability to Enhance Therapy Response in Cancer.

Sofia C Nunes1,2.   

Abstract

Despite all the progresses developed in prevention and new treatment approaches, cancer is the second leading cause of death worldwide, being chemoresistance a pivotal barrier in cancer management. Cancer cells present several mechanisms of drug resistance/tolerance and recently, growing evidence have been supporting a role of metabolism reprograming per se as a driver of chemoresistance. In fact, cancer cells display several adaptive mechanisms that allow the emergency of chemoresistance, revealing cancer as a disease that adapts and evolve along with the treatment. Therefore, clinical protocols that take into account the adaptive potential of cancer cells should be more effective than the current traditional standard protocols on the fighting against cancer.In here, some of the recent findings on the role of metabolism reprograming in cancer chemoresistance emergence will be discussed, as the potential evolutionary strategies that could unable these adaptations, hence allowing to prevent the emergency of treatment resistance, changing cancer outcome.

Entities:  

Keywords:  Adaptation; Cancer; Chemoresistance; Evolution; Metabolism

Year:  2020        PMID: 32130705     DOI: 10.1007/978-3-030-34025-4_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  1 in total

1.  Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.

Authors:  Kwang-Yu Chang; Nai-Jung Chiang; Shang-Yin Wu; Chia-Jui Yen; Shang-Hung Chen; Yu-Min Yeh; Chien-Feng Li; Xiaoxing Feng; Katherine Wu; Amanda Johnston; John S Bomalaski; Bor-Wen Wu; Jianjun Gao; Sumit K Subudhi; Ahmed O Kaseb; Jorge M Blando; Shalini S Yadav; Peter W Szlosarek; Li-Tzong Chen
Journal:  Oncoimmunology       Date:  2021-07-12       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.